Starpharma Holdings Limited

ASX:SPL ISIN:AU000000SPL0

 Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. 
 
     

View in Other Languages

News

Starpharma Holdings (ASX:SPL) Announce Commercial Product Launch Of Priostar(R) Dendrimer Technology As NanoJuiceTM

🕔4/22/2008 9:07:35 AM 2225

Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced the first commercial product launch based on its Priostar(R) dendrimer technology. The product, a research reagent kit called NanoJuiceTM Transfection Kit for transporting DNA into cells, was developed under a license and supply agreement established in February 2007 between Starpharma's wholly owned US subsidiary Dendritic Nanotechnologies (DNT) and EMD Chemicals Inc., an affiliate of Merck KGaA, Darmstadt, Germany.

Read Full Article

Starpharma Holdings (ASX:SPL) Excellence In Biotechnology Investment 2008 Conference - CEO Investor Presentation

🕔4/21/2008 3:07:57 PM 3090

Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) advises that CEO Dr Jackie Fairley is today presenting at the Excellence in Biotechnology Investment 2008 conference in Sydney.

Read Full Article

Starpharma Holdings (ASX:SPL) Studies Show That VivaGel Inhibits Clinically Relevant Strains Of Human Papillomavirus (HPV) In Laboratory Tests

🕔4/21/2008 12:41:58 PM 2648

Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced that recent studies have shown that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits clinically-relevant strains of the human papillomavirus (HPV) in laboratory tests.

Read Full Article

Starpharma Limited (ASX:SPL) Files Patent For Dendrimer Potential in Arthritic Applications

🕔4/14/2008 12:04:29 PM 2804

Starpharma Holdings Ltd (ASX: SPL)(OTCQX: SPHRY) has filed a patent application for the use of SPL7013, the active ingredient in VivaGel(R), to inhibit hyaluronidase activity in the treatment or prevention of a number of diseases. The inhibitory activity was discovered during studies on the contraceptive activity of SPL7013, in which effects on hyaluronidase were examined due to the enzyme's involvement in the fertilization process.

Read Full Article

Starpharma Holdings (ASX:SPL) Signs Research Agreement With Unilever For Dendrimer Technology

🕔4/7/2008 1:24:09 PM 2778

Starpharma Holdings Ltd (ASX:SPL)(OTCQX: SPHRY) today announced the signing of an agreement with Unilever, to co-develop a research tool using Starpharma's Priostar(R) dendrimer technology. An undisclosed fee is payable to Starpharma's US subsidiary DNT Inc as part of the arrangement.

Read Full Article

Starpharma Holdings Limited ASX: SPL - 2007 AGM CEO's Address - Dr Jackie Fairley, CEO

🕔11/15/2007 11:35:00 AM 2031

Starpharma Holdings Limited (ASX: SPL) - 2007 AGM CEO's address - Dr Jackie Fairley, CEO; Starpharma Holdings Limited (ASX: SPL) present the following audio webcast regarding "2007 AGM CEO's address". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Starpharma Holdings Limited ASX: SPL - Co-development Agreement With Durex For Condoms With VivaGel - Dr Jackie Fairley, CEO

🕔10/16/2007 3:21:00 PM 2190

Starpharma Holdings Limited (ASX: SPL) - Co-development Agreement with Durex for Condoms with VivaGel - Dr Jackie Fairley, CEO; Starpharma Holdings Limited (ASX: SPL) present the following audio webcast regarding "Co-development Agreement with Durex for Condoms with VivaGel". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Starpharma Holdings Limited ASX: SPL - US NIH Funded Trial Of VivaGel Commences - Dr Jackie Fairley, CEO

🕔7/11/2007 9:03:00 AM 1740

Starpharma Holdings Limited (ASX: SPL) - US NIH Funded Trial of VivaGel Commences - Dr Jackie Fairley, CEO; Starpharma Holdings Limited (ASX: SPL) present the following audio webcast regarding "US NIH Funded Trial of VivaGel Commences".

Read Full Article

Starpharma Holdings Limited ASX: SPL - Starpharma Joins Premier US OTC Index - Dr Jackie Fairley, CEO

🕔4/3/2007 11:07:00 AM 2104

Starpharma Holdings Limited (ASX: SPL) - Starpharma Joins Premier US OTC Index - Dr Jackie Fairley, CEO; Boardroomradio is pleased to announce that Starpharma Holdings Limited (ASX: SPL) has published an audio file.

Read Full Article

Starpharma Holdings Limited ASX: SPL - 2006 AGM Chairman's Address - Mr Peter Bartels, Chairman

🕔11/15/2006 2:43:00 PM 2209

Starpharma Holdings Limited (ASX: SPL) - 2006 AGM Chairman's Address - Mr Peter Bartels, Chairman; Boardroomradio is pleased to announce that Starpharma Holdings Limited (ASX: SPL) has published an audio file.

Read Full Article
###

120,977 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 73) (Last 30 Days: 352) (Since Published: 31589) 

Company Data

    Headquarters
  • Baker Building
    75 Commercial Road
    Melbourne VIC 3004
    AUSTRALIA
  • Telephone
  • +61 3 8532 2700  
  • Fax
  • +61 3 9510 5955  
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2000/09/28 
  • Homepage
  • www.starpharma.com

More News Results

  • 2024/04/30: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2024/04/17: Change in Director's Interest Notice - R Thomas*
  • 2024/04/16: Change in Director's Interest Notice - R Basser*
  • 2024/04/15: Change in Director's Interest Notice - R Thomas*
  • 2024/04/08: Investor Webinar Notification SPL Medicxi Partnership*
  • 2024/04/08: Starpharma and Medicxi Partnership Petalion Therapeutics*
  • 2024/02/28: Half Yearly Report and Accounts*
  • 2024/02/19: VivaGel BV US FDA Appeal Outcome*
*refer to company website